AzTrials
AzTrials

Well-Being, PsychologicalNCT06002763

Evaluation of Patient-Reported Outcomes Measurement Information System (PROMIS)-29 v2.1 for Postpartum Women

An observational study of Well-Being, Psychological, run by Samuel Lunenfeld Research Institute, Mount Sinai Hospital at 1 site in Canada.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

There is no widely used, statistically validated assessment for physical and mental health for the short- to medium-term in a postpartum population. PROMIS-29 has been validated for the assessment of these factors in a generic population, but has not been specifically evaluated for use with postpartum women. Read more about this study

Who is it for?
Ages 18 to 55 years, women onlyHealthy volunteers can take part
Conditions the study is for
Well-Being, Psychological
What is being tested?
PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System), WHOQoLBREF (World Health Organization Quality of Life Brief Version) and EQ-5D-3L1 (not an acronym)
How many people
200 participants
Where
1 siteCanada
Study dates
9 Jul 2025to Jul 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Study population: Patients who deliver vaginally or by scheduled cesarean section at Mount Sinai Hospital.

Who may be able to join

  • 18 years old and over
  • singleton births
  • 37 or more weeks gestational age
  • multiparous or nulliparous patients
  • spontaneous vaginal delivery or scheduled cesarean delivery with labor analgesia or neuraxial anesthesia
  • give informed written consent

Who cannot join

  • refusal to take part
  • are unable to give or have withdrawn consent
  • patients unable to communicate fluently in English
  • patients who are less than 18 years old
  • patients who had fetal demise or severely morbid fetal conditions such as intubation, cooling, expected surgical correction of congenital anomaly during hospitalization (although NICU admissions will be included)
  • patients who were admitted in ICU
Show all 9Show fewer
  • patients who had failed neuraxial analgesia such as replaced epidurals or failed spinal requiring conversion to general anesthesia
  • patients who had general anesthesia for cesarean delivery as defined by "GETA", including sedatives and deep sedation if not intubated
  • patients who had intrapartum cesarean or had assisted/operative (i.e. vacuum, forceps) vaginal delivery.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Canada1 site, 1 recruiting
  • Mount Sinai Hospital

    Toronto, Ontario, M5G1X5

    Ronald George, MD, 416-586-4800 ext. 2681, ron.george@uhn.ca

    Denise Medeiros, MD

    Recruiting

Other trials in Canada

About this study

There is no widely used, statistically validated assessment for physical and mental health for the short- to medium-term in a postpartum population. PROMIS-29 has been validated for the assessment of these factors in a generic population, but has not been specifically evaluated for use with postpartum women.

This study is a longitudinal, single center observational cohort study designed to evaluate the reliability of the Patient-Reported Outcomes Measurement Information System (PROMIS)-29 v2.1 survey in a postpartum population. PROMIS-29 is a survey designed to screen for pain, impairments in mood, physical function, and activities of daily living. While this survey has shown utility in other populations, it has yet to be assessed in an obstetric population. The investigators plan to recruit patients who are recently postpartum from vaginal or cesarean delivery to complete virtual surveys at defined time points (0, 2, 6, and 12 weeks after delivery). The investigators will subject survey data to statistical measures of validity and reliability comparing with contemporaneously collected surveys of established metrics for quality of life (WHOQoLBREF) and general (global) state of health (numerical rating score 1-100).

The hypothesis is that the PROMIS-29 v2.1 questionnaire is a statistically valid and reliable means of assessing physical and mental health in a postpartum population.

Being tested
PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System), WHOQoLBREF (World Health Organization Quality of Life Brief Version), EQ-5D-3L1 (not an acronym)
Keywords
cesarean delivery, vaginal delivery, postpartum recovery
Medical subject headings
Psychological Well-Being

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System)Other

    Also called Patient-Reported Outcomes Measurement Information System

    PROMIS-29 is a survey designed to screen for pain, impairments in mood, physical function, and activities of daily living.

  • WHOQoLBREF (World Health Organization Quality of Life Brief Version)Other

    Also called World Health Organization Quality of Life Brief Version

    The WHOQOL-BREF is a 26-item version of the 100-item WHOQOL-100 quality of life measure that addresses four quality of life domains: physical health, psychological health, social relationships and environment.

  • EQ-5D-3L1 (not an acronym)Other

    Also called Global state of health numerical rating score 1-100

    The EQ-5D-3L1 is a generic measure of health status consisting of two parts. The first part assesses health in five dimensions: MOBILITY, SELFCARE, USUAL ACTIVITIES, PAIN / DISCOMFORT, ANXIETY/DEPRESSION. The second part of the questionnaire consists of a VAS on which the patient rates their perceived health from 0 (the worst imaginable health) to 100 (the best imaginable health).

Study groups in NCT06002763
Study groupRoleWhat they receive
Vaginal deliveryPatients who have vaginal deliveries with neuraxial labour analgesia.
Receives: Other: PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System); Other: WHOQoLBREF (World Health Organization Quality of Life Brief Version); Other: EQ-5D-3L1 (not an acronym)
Cesarean deliveryPatients who have a scheduled cesarean delivery with neuraxial anesthesia.
Receives: Other: PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System); Other: WHOQoLBREF (World Health Organization Quality of Life Brief Version); Other: EQ-5D-3L1 (not an acronym)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System) survey score

    The PROMIS survey score at 24 hours postpartum

    Measured: 24 hours

  2. WHOQoLBREF (World Health Organization Quality of Life Brief Version) survey score

    The WHOQoLBREF survey score at 24 hours postpartum

    Measured: 24 hours

  3. EQ-5D-3L1 (not an acronym) survey score

    The EQ-5D-3L1 survey score at 24 hours postpartum

    Measured: 24 hours

  4. PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System) survey score

    The PROMIS survey score at 2 weeks postpartum

    Measured: 2 weeks

  5. WHOQoLBREF (World Health Organization Quality of Life Brief Version) survey score

    The WHOQoLBREF survey score at 2 weeks postpartum

    Measured: 2 weeks

  6. EQ-5D-3L1 (not an acronym) survey score

    The EQ-5D-3L1 survey score at 2 weeks postpartum

    Measured: 2 weeks

  7. PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System) survey score

    The PROMIS survey scores at 6 weeks postpartum

    Measured: 6 weeks

  8. WHOQoLBREF (World Health Organization Quality of Life Brief Version) survey score

    The WHOQoLBREF survey score at 6 weeks postpartum

    Measured: 6 weeks

  9. EQ-5D-3L1 (not an acronym) survey score

    The EQ-5D-3L1 survey score at 6 weeks postpartum

    Measured: 6 weeks

  10. PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System) survey score

    The PROMIS survey score at 12 weeks postpartum

    Measured: 12 weeks

  11. WHOQoLBREF (World Health Organization Quality of Life Brief Version) survey score

    The WHOQoLBREF survey score at 12 weeks postpartum

    Measured: 12 weeks

  12. EQ-5D-3L1 (not an acronym) survey score

    The EQ-5D-3L1 survey score at 12 weeks postpartum

    Measured: 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Aug 2023
  2. Study start9 Jul 2025
  3. Primary completionJul 2026 (estimated)
  4. Study completionJul 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06002763
Sponsor's protocol ID
23-03
Status last verified
Jul 2025
First submitted
16 Aug 2023
Last updated
15 Jul 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Well-Being, Psychological, run by Samuel Lunenfeld Research Institute, Mount Sinai Hospital at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 15 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Ronald George, MD (416-586-4800 ext. 2681, ron.george@uhn.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System) survey score (time frame: 24 hours). The study lists 12 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jul 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in